Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 4

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 4
---
 50% performance-based equity;

◦ Adopting an Incentive Compensation Recovery Policy (the “Clawback Policy”);

◦ Adopting stock ownership guidelines for our directors and officers;

◦ Aligning the 2024 performance-based equity incentive to the Company’s financial metrics and commercial pipeline goals;

◦ Mitigating overlapping metrics between the short-term and long-term incentives by adding two new three-year performance metrics to our 2024 performance-based equity program that are separate from the metrics under our short-term incentive program;

◦ Moving from a two-year performance period to a three-year performance period for performance-based equity awards in 2024 and 2025; and

◦ Shifting of our annual grant cycle from the fourth quarter of the fiscal year to the first quarter of the subsequent year to (i) align with our final Board-approved budget, our fiscal year performance period, our goal setting and the reporting of our financial results and (ii) align with our commitment to performance-based equity as noted above.

Each of the above are outlined in more detail in this Proxy Statement. The Compensation Committee will continue to consider stockholder feedback and the outcomes of future Say-on-Pay votes when evaluating our executive compensation programs and practices and making compensation decisions for our executive officers.

#### Castle Biosciences 2025 Proxy Statement3

#### Proxy Summary

### BOARD HIGHLIGHTS
Biographies for Class III Director Nominees (term expiring in 2025)

Set forth below is biographical information for the Class III director nominees. This includes information regarding each director’s experience, qualifications, attributes or skills that led our Board to recommend them for service as a director.

| Name                                          |     | Experience                                                                                                                                                                                                                                      |     | Qualifications, Attributes and Skills             |
| Class III - Term Expiring in 2025             |     |                                                                                                                                                                                                                                                 |     |                                                   |
| Kimberlee S. Caple                            
 Audit Committee                               
 Nominating and Corporate Governance Committee |     | •In March 2025, she retired from her position as the President of the Genetic Science Division, at Thermo Fisher Scientific Inc.                                                                                                                
 •Previously served as the Vice President and General Manager of Genetics Sciences of the Genetics Sciences Business and the Vice President and General manager for the Capillary Electrophoresis Business Unit at Thermo Fisher Scientific Inc. 
 •Holds a B.S degree in biology from Purdue University.                                                                                                                                                                                          |     | •Life Science Industry Experience                 
 •Financial Analysis & Control Experience          
 •Health System